Biostem Financial Statements From 2010 to 2025
| BSEM Stock | USD 15.49 0.49 3.27% |
Check Biostem Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biostem Technologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Biostem financial statements analysis is a perfect complement when working with Biostem Technologies Valuation or Volatility modules.
Biostem |
Biostem Technologies OTC Stock Current Valuation Analysis
Biostem Technologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biostem Technologies Current Valuation | 37.89 M |
Most of Biostem Technologies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostem Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biostem Technologies has a Current Valuation of 37.89 M. This is 99.74% lower than that of the Healthcare sector and 99.18% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.77% higher than that of the company.
Biostem Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biostem Technologies's current stock value. Our valuation model uses many indicators to compare Biostem Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biostem Technologies competition to find correlations between indicators driving Biostem Technologies's intrinsic value. More Info.Biostem Technologies is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biostem Technologies' earnings, one of the primary drivers of an investment's value.About Biostem Technologies Financial Statements
Biostem Technologies investors utilize fundamental indicators, such as revenue or net income, to predict how Biostem OTC Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.